I am not in favor of the R/S, but it's ridiculous to say that's the reason for the recent drop. We traded in the low $3.50's the week after the proposal was announced, down from a close of $3.64 on 3/27. The first week in April was when the biotech selloff started. I'd say the majority of small to bid cap biotechs are off at least 30%-50% from their highs. Here are just a few ... IDRA, ALNY, PCYC, CLDX, ACAD, OXGN, XOMA, ISIS, TKMR, NVAX, ICPT.
Like most, I am very frustrated with the recent price action and it's very easy to say it's because of the R/S, but we would have had a signifigant drop regardless. Everyone has their own theory about the R/S and some have begun to question Dr Kim's motives. Let's not forget what he has accomplished in the last year. I'd say $.50 to $2.26 is pretty impressive. We think about the what the stock price is today. Dr Kim thinks about what the price will be in 6, 12, 24 months. He has consistently delivered for us and I believe he will continue to do so. In the end, it all comes down to the science !!!
the proposal took time to sink in. i think we will drop even more as we approach the RS. its pretty clear ino wants to shake retailers. right now institutions own less than 10% which is unacceptable if kim wants to make ino the next amgen. he doesnt care if retailers lose half their investment in the next year...he is thinking 10 years from now.
My question is who new about the R/S vote before it was posted on that Friday after the market closed? Do you think the Tute that paid the $2.90 for the shelf was aware of it? If they did then I would say they are the short seller from the high $3's back to $2.12..Makes since to me. What better way to suck out retail.